Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P13UK infant immune response study of Prevenar 13 in the UK routine immunization schedule
2010-023865-22Phase 4Completed
- Sponsor
- Health Protection Agency
- Start
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Health Protection Agency. Primary endpoint: Proportion of infants achieving pneumococcal serotype-specific IgG threshold. Started Dec 2010; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2010-023865-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023865-22.